Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Paul R. Walker

Hematology Oncology
600 Moye Blvd, Leo Jenkins Cancer Services Hemtology/oncology, 
Greenville, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Primitive Neuroectodermal Tumor (PNET)
600 Moye Blvd, Leo Jenkins Cancer Services Hemtology/oncology, 
Greenville, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Walker is a Hematologist Oncology provider in Greenville, North Carolina. Dr. Walker is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gamma Knife Radiosurgery, and Endoscopy.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

600 Moye Blvd, Leo Jenkins Cancer Services Hemtology/oncology, Greenville, NC 27834

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Enrollment Status: Completed
Publish Date: January 12, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer
INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer
Enrollment Status: Completed
Publish Date: November 04, 2020
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer
A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 21, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent
A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent
Enrollment Status: Terminated
Publish Date: August 21, 2019
Intervention Type: Other
Study Phase: Phase 2
Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention
Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention
Enrollment Status: Completed
Publish Date: October 13, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 11 Less Clinical Trials

109 Total Publications

Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming.
Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming.
Journal: International journal of molecular sciences
Published: October 04, 2024
Similar Doctors
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Sulochana D. Cherukuri
Hematology Oncology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Sulochana D. Cherukuri
Hematology Oncology | Oncology

Vidant Medical Group LLC

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.2 miles away)
252-847-1757
Languages Spoken:
English
See accepted insurances

Sulochana Cherukuri is a Hematologist Oncology specialist and an Oncologist in Greenville, North Carolina. Dr. Cherukuri is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Pleuropulmonary Blastoma, Lung Nodules, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Gamma Knife Radiosurgery.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Musharraf Navaid
Hematology Oncology | Palliative Medicine | Sleep Medicine
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Musharraf Navaid
Hematology Oncology | Palliative Medicine | Sleep Medicine

Vidant Medical Group LLC

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.2 miles away)
252-847-1757
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Musharraf Navaid is a Hematologist Oncology specialist and a Palliative Medicine provider in Greenville, North Carolina. Dr. Navaid is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Melanoma, Familial Prostate Cancer, Prostate Cancer, Bone Marrow Aspiration, and Prostatectomy. Dr. Navaid is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Pamela A. Lepera
Hematology Oncology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Pamela A. Lepera
Hematology Oncology | Oncology

Vidant Medical Group LLC

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.2 miles away)
252-847-1757
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pamela Lepera is a Hematologist Oncology specialist and an Oncologist in Greenville, North Carolina. Dr. Lepera is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Vaginal Cancer, Colorectal Cancer, Familial Colorectal Cancer, Laryngeal Cancer, and Bone Marrow Aspiration. Dr. Lepera is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walker's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 9 Advanced Conditions
View All 55 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile